Биология ва тиббиёт муаммолари 2025, №2.1 (160)
Тема статьи
ИНСУЛИН РЕЗИСТЕНТЛИКНИНГ ҚАЛҚОНСИМОН БЕЗ САРАТОНИ РИВОЖЛАНИШИДАГИ ЎРНИ: МОЛЕКУЛЯР МЕХАНИЗМЛАР ВА ЭПИДЕМИОЛОГИК МАЪЛУМОТЛАР (200-204)
Авторы
Халимова Замира Юсуфовна, Камилджанова Барнохон Рахимовна
Учреждение
Академик Ё.Х.Турақулов номидаги Республика ихтисослаштирилган эндокринология илмий-амалий тиббиёт маркази, Ўзбекистон Республикаси, Тошкент ш.
Аннотация
Қалқонсимон бези саратони эндокрин тизим билан боғлиқ бўлган энг кенг тарқалган ва бугунги кунда кўпайиб бораётган онкологик касаллик хисобланади. Уни юзага келишига сабачи бўлиши мумкин бўлган омиллар кўп, лекин бугунги кунда уларнинг ичида инсулин резистентлик кўплаб татқиқотчилар этиборини тортган. Шу сабабли инсулин резистентликни қалқонсимон без саратони юзага келишига тасирини ўрганилган кўплаб илмий мақолалар базаси яратилди, ўрганилди, таҳлил қилинди ва қуйидаги мақола ёзилди.
Ключевые слова
қалқонсимон бези саратони, саратон хавф омиллари, инсулин резистентлик.
Литературы
1. Amani Alhozali. Thyroid Cancer, Risk Factors, Clinical Features, Prognosis, and its Incidence Preference in Saudi Populations: Review. Journal of Contemporary Medical Sciences | Vol. 9, No. 6, November–December 2023: 379–384. 2. American Thyroid Association (2022). Thyroid Cancer (Papillary and Follicular) [Brochure]. https://www.thyroid.org/wp-content/uploads/patients/brochures/ThyroidCancer bro-chure.pdf. 3. Belfiore A, Malaguarnera R, Vella V, Lawrence MC, Sciacca L, Frasca F, et al. Insulin receptor isoforms in Physiology and Disease: an updated view. Endocr Rev. 2017;38(5):379–431. 4. Brown JC, Harhay MO, Harhay MN. The Value of An-thropometric Measures in Nutrition and Metabolism: Comment on Anthropometrically Predicted Visceral Adi-pose Tissue and Blood-Based Biomarkers: A Cross-Sectional Analysis. Nutr Metab Insights. 2019;12:1178638819831712. 5. Brenta G, Di Fermo F. Thyroid cancer and insulin re-sistance. Endocrine Research. 2023; 25:19–34. DOI: 10.1007/s11154-023-09849-7. 6. Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014;65:125-37. doi: 10.1146/annurev-med-061512-105739. Epub 2013 Nov 20. PMID: 24274180). 7. Clement S, Refetoff S, Robaye B, Dumont JE, Schurmans S. Low TSH requirement and goiter in trans-genic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology. 2001;142(12):5131–9. 8. Elena D., Silvia R., Leonardo V., Luigino D. Estimating complete cancer prevalence in Europe: validity of alterna-tive vs standard completeness indexes TYPE Original Re-search PUBLISHED 24 April 2023 DOI 10.3389/fonc.2023.1114701. 9. Gandolfi P.P., Frizzina A., Raffa M., Renda F., Roccetti O., Ruggieri S., et al. Incidence of Thyroid Cancer in Multinodular Goiter: A Retrospective Analysis. Acta Bio-med 2004;75:114–117. 10. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thy-roid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. doi: 10.1089/thy.2015.0020. 11. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell prolifera-tion by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev. 2001;22(5):631–56. 12. Kushchayeva YS, Kushchayev SV, Startzell M, Cochran E, Auh S, Dai Y, et al. Thyroid abnormalities in patients with Extreme insulin resistance syndromes. J Clin Endocrinol Metab. 2019;104(6):2216–28. 13. Kushchayeva Y, Kushchayev S, Jensen K, Brown RJ. Impaired glucose Metabolism, anti-diabetes medications, and risk of thyroid Cancer. Cancers (Basel). 2022;14(3). 14. Maenhaut C, Brabant G, Vassart G, Dumont JE. In vitro and in vivo regulation of thyrotropin receptor mRNA levels in dog and human thyroid cells. J Biol Chem. 1992;267(5):3000–7. 15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plas-ma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9. 16. Margarita P., Mengmeng Li, Jerome V., Mathieu L., Dipendra S. Epidemiological Profile of Thyroid Cancer Worldwide: GLOBOCAN Assessment of Incidence and Mortality in 2020. Lancet Diabetes Endocrinol. March 7, 2022. 17. NCI (National Cancer Institute. Physician Data Query (PDQ). Thyroid Cancer Treatment. 02/06/2019. Accessed at https://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq#_313_toc. on February 20, 2019. 18. Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 dia-betes: Time for a conceptual framework shift. Diab Vasc Dis Res. 2019 Mar;16(2):118-127. 19. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212. 10.1155/2013/965212. 20. Park HM, Lee HS, Lee YJ, Lee JH. The triglyceride-glucose index is a more powerful surrogate marker for pre-dicting the prevalence and incidence of type 2 Diabetes Mellitus than the homeostatic model assessment of insulin resistance. Diabetes Res Clin Pract. 2021;180:109042. 21. Seong J, Kang JY, Sun JS, Kim KW. Hypothalamic inflammation and obesity: a mechanistic review. Arch Pharm Res. 2019 May;42(5):383-392. 22. Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304). 23. Szablewski L. Insulin Resistance: The Increased Risk of Cancers. Curr. Oncol. 2024, 31, 998–1027. https://doi.org/10.3390/ curroncol31020075. 24. Thomas DD, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: An Early Indicator of Metabolic Dys-function. J Endocr Soc. 2019 Sep 01;3(9):1727-1747. 25. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, et al. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab. 2002;87(1):245–54. 26. Xu N.,Liu H., Wang Y., and Xue Y. Relationship be-tween insulin resistance and thyroid cancer in Chinese euthyroid subjects without conditions afecting insulin re-sistance. Xu et al. BMC Endocrine Disorders (2022) 22:58 https://doi.org/10.1186/s12902-022-00943-6) 27. Yildirim Simsir I, Cetinkalp S, Kabalak T. Review of Factors Contributing to Nodular Goiter and Thyroid Carci-noma. Med Princ Pract. 2020;29(1):1-5. 28. Zheng R., Zeng H., Zhang S., Chen W. Estimates of cancer incidence and mortality in China, 2013. Chin J. 2017; 36:66. 10.1186/s40880-017-0234-3.